Patents by Inventor Jiwen Zou

Jiwen Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
    Patent number: 11731986
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: August 22, 2023
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
  • INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF
    Publication number: 20230102520
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of LMPTP, compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: July 2, 2020
    Publication date: March 30, 2023
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF
    Publication number: 20230029557
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: June 8, 2021
    Publication date: February 2, 2023
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
    Patent number: 11220486
    Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: January 11, 2022
    Assignees: LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Nunzio Bottini, Jiwen Zou, Santhi R. Ganji, Stephanie Stanford, Anthony Pinkerton, Thomas D. Y. Chung, Michael Hedrick, Robert Ardecky
  • Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
    Patent number: 11066420
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 20, 2021
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
  • INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF
    Publication number: 20200338084
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of LMPTP, compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: January 2, 2019
    Publication date: October 29, 2020
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof
    Publication number: 20200290977
    Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).
    Type: Application
    Filed: February 18, 2020
    Publication date: September 17, 2020
    Inventors: Nunzio BOTTINI, Jiwen ZOU, Santhi R. GANJI, Stephanie STANFORD, Anthony PINKERTON, Thomas D. Y. CHUNG, Michael HEDRICK, Robert ARDECKY
  • Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
    Patent number: 10626094
    Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 21, 2020
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY
    Inventors: Nunzio Bottini, Jiwen Zou, Santhi R. Ganji, Stephanie Stanford, Anthony Pinkerton, Thomas D. Y. Chung, Michael Hedrick, Robert Ardecky
  • Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
    Patent number: 10611733
    Abstract: Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: April 7, 2020
    Assignees: Sanford-Burnham Medical Research Institute, Southern Research Institute
    Inventors: Marintha L. Heil, Nicholas D. P. Cosford, Robert Ardecky, Jiwen Zou
  • INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF
    Publication number: 20200055875
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 20, 2020
    Inventors: Anthony B. PINKERTON, Robert J. ARDECKY, Jiwen ZOU
  • Spirocyclic EBI2 modulators
    Patent number: 10196369
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 5, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • EBI2 modulators
    Patent number: 9776979
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 3, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof
    Publication number: 20170247340
    Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).
    Type: Application
    Filed: October 14, 2015
    Publication date: August 31, 2017
    Inventors: Nunzio BOTTINI, Jiwen ZOU, Santhi R. GANJI, Stephanie STANFORD, Anthony PINKERTON, Thomas CHUNG, Michael HEDRICK, Robert ARDECKY
  • QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS
    Publication number: 20170144978
    Abstract: Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.
    Type: Application
    Filed: February 6, 2017
    Publication date: May 25, 2017
    Inventors: Marintha L. Heil, Nicholas D.P. Cosford, Robert Ardecky, Jiwen Zou
  • Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
    Patent number: 9598402
    Abstract: Provided is a process for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 21, 2017
    Assignees: Southern Research Institute, Sanford-Burnham Medical Research Institute
    Inventors: Marintha L. Heil, Nicholas D. P. Cosford, Robert Ardecky, Jiwen Zou
  • SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS
    Publication number: 20170066731
    Abstract: Provided herein are small molecule Fatty Acid Synthase Inhibitors, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 9, 2017
    Inventors: Nicholas D.P. COSFORD, Jeffrey SMITH, Robert J. ARDECKY, Jiwen ZOU, Margrith MATTMANN, Peter TERIETE, Lester LAMBERT
  • EBI2 MODULATORS
    Publication number: 20160214951
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Application
    Filed: September 26, 2014
    Publication date: July 28, 2016
    Inventors: Anthony B. PINKERTON, Robert ARDECKY, Eduard A. SERGIENKO, Marcos GONZALEZ-LOPEZ, Santhi Reddy GANJI, Jiwen ZOU
  • SPIROCYCLIC EBI2 MODULATORS
    Publication number: 20160176875
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Application
    Filed: September 26, 2014
    Publication date: June 23, 2016
    Inventors: Anthony B. PINKERTON, Robert ARDECKY, Eduard A. SERGIENKO, Marcos GONZALEZ-LOPEZ, Santhi Reddy GANJI, Jiwen ZOU
  • Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
    Patent number: 9193710
    Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: November 24, 2015
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: John Howard Hutchinson, Leo Bleicher, Nick Cosford, Robert John Ardecky, Jiwen Zou
  • NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF
    Publication number: 20150025064
    Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.
    Type: Application
    Filed: August 29, 2012
    Publication date: January 22, 2015
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: John Howard Hutchinson, Leo Bleicher, Nick Cosford, Robert John Ardecky, Jiwen Zou